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ess under CC BY-NC-Abstract Borneol is a traditional Chinese medicine that can promote drug absorption from the gastrointestinal
tract and distribution to the brain. However, stomach irritation may occur when high doses of borneol are used. In
the present work, gastrodin, the main bioactive ingredient of the traditional Chinese drug “Tianma” (Rhizoma
Gastrodiae) was used as a model drug to explore reasonable application of borneol. Sustained-release solid
dispersions (SRSDs) for co-loading gastrodin and borneol were prepared using ethylcellulose as a sustained
release matrix and hydroxy-propyl methylcellulose as a retarder. The dispersion state of drug within the SRSDs
was analyzed by using scanning electron microscopy, differential scanning calorimetry, and powder X-ray
diffractometry. The results indicated that both gastrodin and borneol were molecularly dispersed in an amorphous
form. Assay of in vitro drug release demonstrated that the dissolution proﬁles of gastrodin and borneol from the
SRSDs both ﬁtted the Higuchi model. Subsequently, gastric mucosa irritation and the brain targeting of the
SRSDs were evaluated. Compared with the free mixture of gastrodin and borneol, brain targeting of SRSDs was
slightly weaker (brain targeting index: 1.83 vs. 2.09), but stomach irritation obviously reduced. Sustained-release
technology can be used to reduce stomach irritation caused by borneol while preserving sufﬁcient transport
capacity for oral brain-targeting drug delivery.
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Preparation and evaluation of gastrodin with borneol 871. Introduction
In many compounds employed in traditional Chinese medicine (TCM),
a so-called messenger drug is usually included. It is capable of
introducing the main effective drugs in the prescription to the target site
to increase therapeutic efﬁcacy1–3. The bicyclic monoterpene borneol
(Fig. 1A) is one such messenger drug that is frequently used in the
treatment of encephalopathy like stroke, epilepsy and headache. Studies
have shown that borneol can promote drug absorption from the
gastrointestinal tract and facilitate distribution to the brain4–8. However,
stomach irritation may occur when a high dose of borneol is used9,10,
which limits the clinical application of borneol as an oral brain-
targeting enhancer.
Gastrodin (p-hydroxymethylphenyl-β-D-glucopyranoside, Fig.
1B), the main bioactive ingredient of the traditional Chinese drug
“Tianma” (Rhizoma Gastrodiae), is used in the treatment of some
central nervous system disorders, such as vertigo, headache,
insomnia, neuralgia, neurasthenia and epilepsy in TCM11–13.
Gastrodin has attracted increasing attention because of its low
toxicity and therapeutic efﬁcacy. Gastrodin acts on the brain to
produce central inhibitory effects, but it does not easily pass through
the blood–brain barrier (BBB) due to its hydrophilicity. In fact, the
drug concentration in brain after administration is far lower than in
other tissues14,15. Enhancing the delivery of gastrodin to the brain
could improve therapeutic efﬁcacy.
Our previous work indicated that 400 mg/kg of borneol can
accelerate the absorption of gastrodin (200 mg/kg) in mice gastro-
intestinal tract and promote its distribution to the brain4. In this study,
gastrodin was still used as a model drug to explore reasonable
application of borneol as an oral brain-targeting enhancer. Sustained-
release technology is one of the efﬁcient methods for decreasing
stomach irritation by drugs16,17. The solid dispersion technique using
water-insoluble carriers can be used to sustain the drug release and
reduce drug side effects18. A sustained-release solid dispersion (SRSD)
medium was designed for co-loading gastrodin with borneol. The
SRSDs were prepared using ethylcellulose (EC) as a sustained-release
matrix and hydroxypropyl methylcellulose (HPMC) as a retarder.
The physicochemical characterization, levels of gastric mucosa irrita-
tion, and brain targeting effect of borneol on gastrodin within the
SRSDs was evaluated.2. Materials and methods
2.1. Materials and animals
Synthetic borneol was purchased from Guangzhou Chemical
Industrial Co. (Guangzhou, China). Gastrodin (purity 99.7%)Figure 1 Chemical structures of borneol (A) and gastrodin (B).was synthesized and analyzed for purity by Kunming Pharmaceu-
tical Co. (Kunming, China). Ethylcellulose (EC, 100 cp) and
hydroxy-propyl methylcellulose (HPMC, K100M) were kindly
provided by Shanghai Colorcon Coating Technology Co., Ltd.
(Shanghai, China). Gastrodigenin (purity 99.5%) was purchased
from Dingxin Chemical Industrial Co. (Yizheng, China). Hydro-
quinone (purity 99.4%) was purchased from Sanjili Chemical
Industrial Co. (Lianyungang, China) and used as the internal
standard solution (100 μg/mL in methanol). Water was deionized
and double distilled. Other chemical reagents were of chromato-
graphic or analytical grade and commercially available.
Healthy male Sprague-Dawley rats (230–270 g) and male
Kunming strain mice (18–22 g) were obtained from the Laboratory
Animal Center of Southern Medical University (SCXK 2006-
0015, China). Prior to experimentation, animals were acclimated
for at least 1 week to a 12 h light/dark cycle with free access to
standard chow and water. The animals were fasted overnight
but supplied with water ad libitum before the experiments. All
experimental protocols were approved by the Institutional Animal
Care and Use Committee of Southern Medical University.
2.2. Preparation of the SRSDs
The SRSDs were prepared by conventional solvent evaporation
method. Gastrodin, borneol, EC and HPMC at a weight ratio of
1:2:4:1 were mixed and dissolved in a minimum volume of
ethanol in a beaker. The solvent was removed at 30 1C in a
vacuum oven until there was no alcohol smell. The dried
dispersion was kept in refrigerator (20 1C) for 2 days to harden.
The resultant solid dispersions were pulverized with a mortar and
pestle, sieved to obtain 40–60 mesh particles, and then stored in a
desiccator at room temperature.
2.3. Scanning electron microscopy
Representative scanning electron microscope (SEM) images of the
samples, including the physical mixture of drugs with excipients
and the SRSDs, were taken using a JSM-5900LV SEM (Jeol,
Tokyo, Japan) at 20 kV acceleration voltage without Au or Pt
coating. For the SEM observations, each sample was ﬁxed on an
aluminum sample holder using double-side carbon tape.
2.4. Differential scanning calorimetry
The thermal behavior of drug formulations are important in
pharmaceutical technologies, since the obtained information such
as melting, recrystallization, decomposition, or a change in heat
capacity could help to ascertain the physicochemical status of the
entrapped drug inside the excipient. Differential scanning calori-
metry (DSC) measurements were performed using a DSC-Q100
(TA instruments, New Castle, DE, USA). The DSC thermograms
were collected from a 3 mg sample held in a sealed aluminum pan.
The thermograms were generated at a heating rate of 20 1C/min
from 0 to 270 1C with nitrogen purge at 50 mL/min. An empty
aluminum pan was used as reference.
2.5. Powder X-ray diffractometry
In order to determine whether the drugs were amorphous or
crystalline within the formulation, powder X-ray diffractometry
(PXRD) study was conducted for the pure drug, the polymers, the
Z. Cai et al.88physical mixture of drugs and polymers and the SRSDs. The
PXRD patterns were obtained by using an X-ray diffractometer
(D/Max-rA, Rigaku, Tokyo, Japan) with Nickel ﬁltered Cu-Kα line
as the source of radiation, operated at 40 kV voltage and a current
of 100 mA. The samples were analyzed in the 2θ angle range of
0–501 at a step size of 0.021 and scanning speed of 41/min.
2.6. In vitro drug release test
The drug release tests of the SRSDs were carried out by the paddle
method speciﬁed in the Chinese Pharmacopoeia at a paddle rotation
speed of 100 rpm in 900 mL distilled water at 3770.5 1C. The SRSDs
were weighed so as to contain 20 mg of gastrodin. At the speciﬁed
time (0.5, 1, 2, 4, 6 and 8 h), 8 mL of the dissolution medium was
sampled, and fresh medium (8 mL) prewarmed at 37 1C was
simultaneously added to the dissolution medium to maintain a constant
volume throughout the test. The sample was ﬁltered with a membrane
ﬁlter (0.45 μm). Aliquots of 2.5 mL were withdrawn and assayed for
borneol content by gas chromatograph (GC-122, Factory of Analytical
Apparatus, Shanghai, China)19. The remaining ﬁltrate was assayed for
gastrodin content by measuring the absorbance at 221 nm on a UV–
visible spectrophotometer (UV2201, Shimadzu, Japan).
To analyze the in vitro release data, various kinetic models
including the zero-order model (Eq. (1)), the ﬁrst-order model
(Eq. (2)) and the Higuchi model (Eq. (3)) were used to describe the
release kinetics20.
R¼ kt ð1Þ
ln UR¼ kt ð2Þ
R¼ kt1=2 ð3Þ
In these equations, R and UR are the released and unreleased
percentages at time (t) and k is the rate constant.
2.7. Gastric mucosa irritation test
Twelve Sprague-Dawley male rats were divided randomly into
4 groups, 3 rats per group, and intragastrically administered various
drug combinations and doses twice a day for 4 days. Group 1 was
administered 20 mL/kg physiological saline, group 2 was adminis-
tered 300 mg/kg gastrodin, group 3 was administered 300 mg/kg of
gastrodin and 600 mg/kg borneol, and group 4 was administered
SRSDs containing 300 mg/kg of gastrodin and 600 mg/kg of
borneol. Drug solutions and suspensions were prepared with 1%
CMC-Na solution and given in equal volume of 20 mL/kg.
On the ﬁfth day, the animals were anaesthetized with ether and
the stomach was removed. The resected stomach was opened
along the lesser curvature and a mucosal specimen (about 0.5 cm2)
was obtained. The specimen was rinsed in physiological saline and
then ﬁxed overnight in 2.5% glutaraldehyde. Subsequently, the
specimen was dehydrated through an ethanol series (30%–100%),
substituted with isoamyl acetate, critical point dried with CO2, and
sputter coated with gold. The prepared specimens were observed
with a scanning electron microscope (Amray 1000B, Bedford,
MA, USA). The rest of the stomach tissue was ﬁxed in 4%
paraformaldehyde after being washed in physiological saline. A
strip of stomach sample containing sinus ventriculi and corpus
gastricum was cut from the lesser curvature, and embedded in
parafﬁn. Sections with the thickness of 5 μm were cut for light
microscopic evaluation.2.8. In vivo pharmacokinetics study
All mice were divided randomly into 3 groups, 40 mice each
group, and intragastrically administered as follows: gastrodin
group, administered 200 mg/kg of gastrodin; physical mixture
group, administered 200 mg/kg gastrodin with 400 mg/kg borneol;
SRSDs group, administered SRSDs containing 200 mg/kg of
gastrodin and 400 mg/kg borneol. Drug solutions and suspensions
were prepared with 1% CMC-Na solution in equal volume.
At the indicated time points (2, 5, 15, 30, 60, 120, 180 and
300 min) following intragastric administration, 5 mice were
sampled from each group. After anaesthetization, blood was
collected from orbital venous plexus, drawn into a heparinized
centrifuge tube and centrifuged at 500 g for 10 min. About 200–
300 μL plasma was obtained. After blood collection, the animals
were euthanized by cervical dislocation. Brain tissue was imme-
diately collected, washed with physiological saline and dried with
ﬁlter paper. The plasma and brain tissue samples were stored at
20 1C until analysis.
The brain tissue samples were weighed and homogenized in
physiological saline (0.5 g/mL). Brain homogenate (500 μL) was
mixed with the internal standard solution (10 μL) in a centrifuge
tube. Gastrodigenin and the internal standard were extracted in
3 mL of ethyl acetate by vortex mixing for 3 min. After centrifu-
gation at 1000 g for 5 min, 2.5 mL of supernatant was obtained
and evaporated under air stream in a water bath at 50 1C. The
residue was reconstructed in 200 μL of methanol. After centri-
fuged at 8000 g for 10 min, a 20 μL aliquot of supernatant was
injected into the HPLC system for analysis.
The concentrations of gastrodin in the plasma and gastrodigenin in
the brain were determined according to a previously described
method4. The analysis was performed on an Agilent 1100 series
HPLC system (Agilent Technologies, USA) equipped with a quatern-
ary pump, a vacuum degasser, a column thermostat, a 20 μL injector
loop, a UV detector and HP ChemStation software. The separation was
carried out using a Diamonsil C18 column (250 mm 4.6 mm, i.d.,
5.0 μm, Dikma Technologies, China) under the following chromato-
graphic conditions: column temperature, 25 1C; sample injection
volume, 20 μL; ﬂow rate, 1.0 mL/min; detection wavelength,
221 nm; mobile phase, acetonitrile–water. The contents of acetonitrile
in mobile phase were 6.5% (v/v) for gastrodin and 10.5% for
gastrodigenin. Data were acquired and processed by HP ChemStation
software, and the each analyte was quantiﬁed by the ratio of the analyte
peak area to that of the internal standard. The method used for analyses
were validated over a concentration range 1.5–500 μg/mL for gastrodin
in plasma, and a concentration range 0.05–1.5 μg/mL for gastrodigein
in brain. Intra- and inter-day precision (%RSD) were within 5% and
the accuracy ranged 92%–104%.
The pharmacokinetic parameters were estimated by non-
compartmental methods using 3P97 software. The area under the
concentration–time curve (AUC) was calculated up to the last data
point using trapezoidal method without extrapolation to inﬁnity.
The standard deviation of AUC was calculated as described21.
The mean residence time (MRT) was calculated as follows:
MRT¼AUMC/AUC where AUMC is the area under the ﬁrst
moment–time curve. Peak concentration (Cmax) and peak time
(Tmax) were derived directly from the original measured values.
The relative bioavailabilities (F) of gastrodin in the plasma and
gastrodigenin in the brain were calculated as the ratio of AUCGþB/
AUCG (“GþB” meant administration of gastrodin combined with
borneol and “G” meant administration of gastrodin alone). The brain
Preparation and evaluation of gastrodin with borneol 89targeting efﬁciency was evaluated using brain targeting index (BTI)
described as follows: BTI¼ (AUCBr(GþB)/AUCP(GþB))/(AUCBr(G)/
AUCp(G)) (“Br” meant brain and “P” meant plasma), and the value
of BTI41 was considered brain targeting distribution.
2.9. Statistical analysis
The data in this paper were presented as mean7SD, if not
otherwise speciﬁed. Signiﬁcant differences were assessed by using
one-way ANOVA. A probability value of Po0.05 was considered
to be statistically signiﬁcant.3. Results and discussion
3.1. Preparation of the SRSDs
Ethylcellulose has been widely used in the production of
sustained-release matrices, because it is insoluble in water and
well tolerated by patients. Conversely, HPMC is a hydrophilic
polymer that can retard drug release by swelling in water. In our
previous work, we found that the optimal ratio of gastrodin and
borneol was 1:24, and it was reported that the optimal ratio of drug
to polymer in solid dispersions was usually in the range of 1:1–
1:320. Therefore, the formula of the SRSDs was designed and
optimized as follows: gastrodin: borneol: EC: HPMC at a ratio
(w/w) of 1:2:4:1. Both gastrodin and borneol are readily soluble in
ethanol, as is EC. So it was suitable to prepare the SRSDs by
solvent evaporation method. Drug release rate became slowerFigure 2 Scanning electron microphotographs of physical mwhen grain size of the SRSDs was increased. However,
big particles were difﬁcult to be administered to mice or rats.
Therefore, the SRSDs were sieved to obtain 40–60 mesh particles.
3.2. Physicochemical characterization of the SRSDs
Scanning electron micrographs revealed clear changes in the
morphology of the drugs and excipients in different formulations.
In the physical mixture, separate gostrodin, borneol and polymers
crystals were clearly seen (Fig. 2A), whereas the solid
dispersions exhibited the appearance of typical ﬂaky material
(Fig. 2B).
The physical state of drugs in the SRSDs was further evaluated
by DSC and PXRD. The DSC thermograms are shown in Fig. 3.
Gastrodin produced a large melting endotherm at 157.9 1C.
However, the SRSDs did not display any thermal event around
this temperature. This indicated that gastrodin was present in an
amorphous state. The DSC thermogram of the excipients showed a
broad peak probably due to presence of water. The dispersion state
of borneol in the SRSDs could not be evaluated by DSC due to its
volatility.
The PXRD pattern of pure borneol indicated that borneol was
crystalline as demonstrated by several distinctive peaks observed
at 2θ of 13.921, 15.111, and 16.181 (Fig. 4B). Moreover, the
physical mixture of drugs and excipients showed the same series
of three peaks. In contrast, all these characteristic peaks of borneol
were absent in the diffraction spectrum of the SRSDs, suggesting
that borneol was not in crystalline form. These ﬁndings demon-
strated that both gastrodin and borneol in the SRSDs wereixture of drugs with EC and HPMC (A) and the SRSDs (B).
Figure 3 Differential scanning calorimetry thermograms of gastrodin
(A), borneol (B), ECþHPMC (C), physical mixture of drugs with EC
and HPMC (D) and the SRSDs (E).
Figure 4 Powder X-ray patterns of gastrodin (A), borneol (B),
ECþHPMC (C), physical mixture of drugs with EC and HPMC (D)
and the SRSDs (E).
Figure 5 In vitro dissolution proﬁles of gastrodin and borneol from
the physical mixture of drugs with excipients and the SRSDs (n¼6).
Table 1 Regression parameters obtained from ﬁt of release
data to various kinetic models.
Kinetic model Gastrodin Borneol
k R k R
Zero-order model 7.921 0.8439 9.361 0.9673
First-order model 2.916 0.9782 4.244 0.9975
Higuchi model 2.970 0.9558 3.198 0.9982
Z. Cai et al.90molecularly dispersed in an amorphous form, thus conﬁrming the
formation of solid dispersions.3.3. Drug release behavior of the SRSDs
The mean cumulative release of gastrodin and borneol with time is
shown in Fig. 5. The SRSDs were able to sustain drugs release for
8 h. The release rate of gastrodin was higher than that of borneol,
because gastrodin is readily soluble in water. Indeed, more than
60% of gastrodin was released within 2 h. These SRSDs in powder
show signiﬁcant sustained-release effect compared to crude drugs.
They could be reformulated for oral dosage (tablets, capsules and
pills) that might provide better control of drug release rate.
Table 1 lists the regression parameters obtained after ﬁtting the
different release kinetic models to the in vitro dissolution data. The
goodness of ﬁt for various models was investigated for gastrodin
and borneol. In vitro release data of gastrodin and borneol best
ﬁtted the ﬁrst-order model. It was demonstrated that the SRSDs
possessed matrix structure, from which the dissolved drug diffused
into the dissolution medium.3.4. Gastric mucosa irritation of the SRSDs
The scanning electron micrographs of gastric mucosa are shown in
Fig. 6. There were no abnormalities found in the gastrodin and
SRSDs groups compared with the physiological saline group.
However, visible gastric mucosa stripping was observed in the
group treated with the physical mixture of gastrodin and borneol.
The acute toxicity test dose of borneol used in this study was
nearly 100 times higher than that for clinical use. In fact, the
clinical gastric irritation reaction was frequently met, but not as
serious as was observed in this study.
Histopathological examination of the stomach (Fig. 7) did not
reveal any abnormalities in the physiological saline or gastrodin
group. However, there was obvious multifocal necrosis in the
mixture group, supporting the result from SEM analysis. In
addition, a slight focal necrosis was recognized in the SRSDs
group, which was not observed in the scanning electron micro-
graph. These results indicated that high dose of borneol had
signiﬁcant toxicity to gastric mucosa and the irritation was reduced
when borneol was entrapped in the sustained-release matrix.3.5. Brain-targeting effect of the SRSDs
Gastrodin cannot bind to benzodiazepine receptors directly. In
brain, gastrodin is rapidly metabolized into gastrodigenin (p-
hydroxybenzylalcohol) which can bind to benzodiazepine recep-
tors in vivo and induce central inhibitory effects22–24. Therefore,
the gastrodin concentrations in the plasma and gastrodigenin
concentrations in the brain were determined to evaluate the
distribution of gastrodin in mice.
Both borneol and gastrodin are low toxic drugs. The oral LD50 of
borneol for mice is 3830 mg/kg25, and the oral LD50 of gastrodin
is higher than 5000 mg/kg. Therefore, co-administration of 200 mg/kg
Figure 6 Scanning electron microphotographs (500 ) of gastric mucosa of rats after intragastric administration of physiological saline (A),
gastrodin (B), physical mixture of gastrodin and borneol (C) and the SRSDs (D).
Figure 7 Pathological microphotographs (400 ) of gastric mucosa
of rats after intragastric administration of physiological saline (A),
gastrodin (B), physical mixture of gastrodin and borneol (C) and the
SRSDs (D).
Preparation and evaluation of gastrodin with borneol 91gastrodin and 400 mg/kg borneol is safe for mice in the phar-
macokinetics study.
The concentration–time proﬁles of gastrodin in the plasma and
gastrodigenin in brain after intragastric administration of gastro-
din alone, physical mixture of gastrodin and borneol, and the
SRSDs are shown in Figs. 8 and 9. The pharmacokinetic
parameters calculated by statistical moment analysis are shown
in Tables 2–4.
The pharmacokinetic parameters of gastrodin group (negative
control) and physical mixture group (positive control) were similar
to those found in previous study4. Compared to administration of
gastrodin alone, gastrodin co-administrated with borneol was
rapidly absorbed from the gastrointestinal tract. The Tmax of
gastrodin in plasma reduced to 5 min from 30 min, while the
AUC of gastrodigenin in mouse brain was increased by 105.6%.
Thus, an obvious brain targeting effect was observed. Because the
absolute oral bioavailability of gastrodin is as high as 80%26, there
was no signiﬁcant difference in Cmax and AUC for gastrodin in the
plasma between gastrodin administered alone and co-administrated
with borneol.
Compared to gastrodin group, relative bioavailability of the
SRSDs was 94.8%, indicating that gastrodin in the SRSDs was
released and absorbed almost completely. Gastrodin is easily
soluble in water, and it can be absorbed fast in the intestinal tract.
Burst effect might occur, so Tmax showed no difference between
gastroin group and the SRSD group. Compared with the mixture
group, the Tmax of gastrodin in plasma and gastrodigenin in mouse
brain were delayed 25 min due to sustained-release of borneol, but
there was no signiﬁcant difference in AUC and BTI between the
Figure 8 The concentration–time proﬁles of gastrodin in mice
plasma after intragastric administration of gastrodin alone, physical
mixture of gastrodin and borneol, and the SRSDs, respectively (n¼5).
Figure 9 The concentration–time proﬁles of gastrodigenin in mice
brain after intragastric administration of gastrodin alone, physical
mixture of gastrodin and borneol, and the SRSDs, respectively
(n¼5).
Table 2 Pharmacokinetic parameters of gastrodin in mice plasma after intragastric administration of gastrodin alone, physical mixture of
gastrodin and borneol, and the SRSDs, respectively (n¼5).
Parameter Gastrodin group Physical mixture group SRSDs group
Cmax (μg/mL) 162.39731.85 168.54761.84 154.43741.89
Tmax (min) 30 5 30
AUC (μg·min/mL) 18,46472028 181,74572273 17,50472881
MRT (min) 104.4 115.5 107.1
Table 3 Pharmacokinetic parameters of gastrodigenin in mice brain after intragastric administration of gastrodin alone, physical mixture
of gastrodin and borneol, and the SRSDs, respectively (n¼5).
Parameter Gastrodin group Physical mixture group SRSDs group
Cmax (μg/mL) 0.4870.15 0.6170.21 0.5870.16
Tmax (min) 15 5 30
AUC (μg·min/mL) 49.58710.86 101.96716.17nn 86.12715.64nn
MRT (min) 77.27 136.29 123.48
nnCompared with gastrodin group: Po0.01.
Table 4 The relative bioavailabilities and brain targeting indexes for oral administration of gastrodin alone, physical mixture of gastrodin
and borneol, and the SRSDs, respectively (n¼5).
Parameter Gastrodin group Physical mixture group SRSDs group
F (gastrodin in plasma, %) 100.0 98.4 94.8
F (gastrodigenin in brain, %) 100.0 205.6 173.7
BTI 1.00 2.09 1.83
Z. Cai et al.92two groups. The results indicated that the SRSDs preserved
sufﬁcient transport capacity for oral brain-targeting drug delivery.
Borneol likely promotes drug transport through biological
membranes such as gastrointestinal mucosa and the blood–brain
barrier by transiently loosening intercellular tight junctions of the
membranes27,28. This could cause an irritation reaction, when a
large amount of borneol acts on the membrane simultaneously.
Therefore, sustained-release of borneol might avoid irreversibly
altering the structure of multicellular membranes.4. Conclusions
Borneol can accelerate the absorption of gastrodin through the
gastrointestinal mucosa and promote its transport across the BBB into
the brain. However, gastric mucosa irritation results from high doses of
borneol. Stomach irritation can be reduced by using solid dispersion
techniques to promote sustain release of borneol. The brain targeting
effect of borneol was not signiﬁcantly changed, although it is
incorporated in the solid dispersions. In conclusion, sustained-release
Preparation and evaluation of gastrodin with borneol 93technology can be used to reduce stomach irritation caused by borneol,
making it more suitable for practical application in oral brain-targeting
drug delivery. This study provides a strategy for preparation and
application of those traditional Chinese medicines with slight irritation
or toxicity.
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